Title: Pimavanserin for the treatment of Parkinson's disease psychosis.
Journal: Expert opinion on pharmacotherapy 20131001
Title: Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Journal: Schizophrenia research 20121101
Title: Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120901
Title: Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Journal: Behavioural pharmacology 20120801
Title: Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Journal: Behavioural pharmacology 20111001
Title: Serotonin 2A receptor antagonists for treatment of schizophrenia.
Journal: Expert opinion on investigational drugs 20110901
Title: Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
Journal: Sleep medicine 20110201
Title: Parkinson's disease dementia.
Journal: Current neurology and neuroscience reports 20100701
Title: Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100301
Title: Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
Journal: The Journal of pharmacology and experimental therapeutics 20100201
Title: Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Journal: Expert opinion on pharmacotherapy 20081201
Title: A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Journal: Pharmacology, biochemistry, and behavior 20081001
Title: PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
Journal: The international journal of neuropsychopharmacology 20080301
Title: Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Journal: The American journal of psychiatry 20080301
Title: ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Journal: The Journal of pharmacology and experimental therapeutics 20070801
Title: The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
Journal: Journal of clinical pharmacology 20070701
Title: Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.
Journal: Journal of clinical pharmacology 20070601
Title: ACP-103, a 5-HT2A receptor inverse agonist.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060701
Title: Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Journal: The Journal of pharmacology and experimental therapeutics 20060501
Title: Vanover KE, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP- 103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8.
